Lipid lowering drugs and inflammatory changes: an impact on cardiovascular outcomes?

References

• Libby P. Inflammation in atherosclerosis. Arteriosclerosis, Thrombosis, and Vascular Biology. 2012;32:2045–2051.
   PubMed Web of Science ®Google Scholar
• Ridker PM, Rifai N, Clearfield M, et al. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med. 2001;344:1959–1965.
   PubMed Web of Science ®Google Scholar
• Libby P, Ridker PM, Hansson GK. Leducq transatlantic network on A. Inflammation in atherosclerosis: from pathophysiology to practice. J Am Coll Cardiol. 2009;54:2129–2138.
   PubMed Web of Science ®Google Scholar
• Ridker PM. Residual inflammatory risk: addressing the obverse side of the atherosclerosis prevention coin. Eur Heart J. 2016;37:1720–1722.
   PubMed Web of Science ®Google Scholar
• Emerging Risk Factors C, Kaptoge S, Di Angelantonio E, Lowe G, et al. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet. 2010;375:132–140.
   PubMed Web of Science ®Google Scholar
• Kinlay S. Low-density lipoprotein-dependent and -independent effects of cholesterol-lowering therapies on C-reactive protein: a meta-analysis. J Am Coll Cardiol. 2007;49:2003–2009.
   PubMed Web of Science ®Google Scholar
• Nordestgaard BG, Varbo A. Triglycerides and cardiovascular disease. Lancet. 2014;384:626–635.
   PubMed Web of Science ®Google Scholar
• Silverman MG, Ference BA, Im K, et al. Association between lowering LDL-C and cardiovascular risk reduction among different therapeutic interventions: a systematic review and meta-analysis. JAMA. 2016;316:1289–1297.
   PubMed Web of Science ®Google Scholar
• Navarese EP, Robinson JG, Kowalewski M, et al. Association between baseline LDL-C level and total and cardiovascular mortality after LDL-C lowering: a systematic review and meta-analysis. JAMA. 2018;319:1566–1579.
   PubMed Web of Science ®Google Scholar
• Ference BA, Cannon CP, Landmesser U, et al. Reduction of low density lipoprotein-cholesterol and cardiovascular events with proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors and statins: an analysis of FOURIER, SPIRE, and the Cholesterol Treatment Trialists Collaboration. Eur Heart J. 2018;39:2540–2545.
   PubMed Web of Science ®Google Scholar
• Ray KK, Kastelein JJ, Boekholdt SM, et al. The ACC/AHA 2013 guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk in adults: the good the bad and the uncertain: a comparison with ESC/EAS guidelines for the management of dyslipidaemias 2011. Eur Heart J. 2014;35:960–968.
   PubMed Web of Science ®Google Scholar
• Patel R, Janoudi A, Vedre A, et al. Plaque rupture and thrombosis are reduced by lowering cholesterol levels and crystallization with ezetimibe and are correlated with fluorodeoxyglucose positron emission tomography. Arteriosclerosis, Thrombosis, and Vascular Biology. 2011;31:2007–2014.
   PubMed Web of Science ®Google Scholar
• Janoudi A, Shamoun FE, Kalavakunta JK, et al. Cholesterol crystal induced arterial inflammation and destabilization of atherosclerotic plaque. Eur Heart J. 2016;37:1959–1967.
   PubMed Web of Science ®Google Scholar
• Ferri N, Corsini A, Sirtori CR, et al. Present therapeutic role of cholesteryl ester transfer protein inhibitors. Pharmacol Res. 2018;128:29–41.
   PubMed Web of Science ®Google Scholar
• Crea F, Liuzzo G. Pathogenesis of acute coronary syndromes. J Am Coll Cardiol. 2013;61:1–11.
   PubMed Web of Science ®Google Scholar
• Duewell P, Kono H, Rayner KJ, et al. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature. 2010;464:1357–1361.
   PubMed Web of Science ®Google Scholar
• Hansson GK. Inflammatory mechanisms in atherosclerosis. J Thromb Haemost. 2009;7(Suppl 1):328–331.
   PubMedGoogle Scholar
• Libby P, Hansson GK. Taming Immune and Inflammatory Responses to Treat Atherosclerosis. J Am Coll Cardiol. 2018;71:173–176.
   PubMed Web of Science ®Google Scholar
• Fuster JJ, MacLauchlan S, Zuriaga MA, et al. Clonal hematopoiesis associated with TET2 deficiency accelerates atherosclerosis development in mice. Science. 2017;355:842–847.
   PubMed Web of Science ®Google Scholar
• Coll RC, Robertson AA, Chae JJ, et al. A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases. Nat Med. 2015;21:248–255.
   PubMed Web of Science ®Google Scholar
• Wang YI, Schulze J, Raymond N, et al. Endothelial inflammation correlates with subject triglycerides and waist size after a high-fat meal. Am J Physiol Heart Circ Physiol. 2011;300:H784–H791.
   PubMed Web of Science ®Google Scholar
• Varbo A, Benn M, Tybjaerg-Hansen A, et al. Elevated remnant cholesterol causes both low-grade inflammation and ischemic heart disease, whereas elevated low-density lipoprotein cholesterol causes ischemic heart disease without inflammation. Circulation. 2013;128:1298–1309.
   PubMed Web of Science ®Google Scholar
• Chapman MJ, Ginsberg HN, Amarenco P, et al. Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. Eur Heart J. 2011;32:1345–1361.
   PubMed Web of Science ®Google Scholar
• Nordestgaard BG. Triglyceride-Rich Lipoproteins and Atherosclerotic Cardiovascular Disease: New Insights From Epidemiology, Genetics, and Biology. Circ Res. 2016;118:547–563.
   PubMed Web of Science ®Google Scholar
• Jun M, Foote C, Lv J, et al. Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis. Lancet. 2010;375:1875–1884.
   PubMed Web of Science ®Google Scholar
• Nordestgaard BG, Langsted A. Lipoprotein (a) as a cause of cardiovascular disease: insights from epidemiology, genetics, and biology. J Lipid Res. 2016;57:1953–1975.
   PubMed Web of Science ®Google Scholar
• Cao J, Steffen BT, Budoff M, et al. Lipoprotein(a) levels are associated with subclinical calcific aortic valve disease in white and black individuals: the multi-ethnic study of atherosclerosis. Arterioscler Thromb Vasc Biol. 2016;36:1003–1009.
   PubMed Web of Science ®Google Scholar
• von Eckardstein A. Will you, nill you, I will treat you: the taming of lipoprotein(a). Eur Heart J. 2017;38:1570–1572.
   PubMed Web of Science ®Google Scholar
• Nordestgaard BG, Chapman MJ, Ray K, et al. Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J. 2010;31:2844–2853.
   PubMed Web of Science ®Google Scholar
• Lanktree MB, Rajakumar C, Brunt JH, et al. Determination of lipoprotein(a) kringle repeat number from genomic DNA: copy number variation genotyping using qPCR. J Lipid Res. 2009;50:768–772.
   PubMed Web of Science ®Google Scholar
• Mack S, Coassin S, Rueedi R, et al. A genome-wide association meta-analysis on lipoprotein (a) concentrations adjusted for apolipoprotein (a) isoforms. J Lipid Res. 2017;58:1834–1844.
   PubMed Web of Science ®Google Scholar
• Feingold KR, Moser AH, Shigenaga JK, et al. Inflammation stimulates the expression of PCSK9. Biochem Biophys Res Commun. 2008;374:341–344.
   PubMed Web of Science ®Google Scholar
• Coassin S, Erhart G, Weissensteiner H, et al. A novel but frequent variant in LPA KIV-2 is associated with a pronounced Lp(a) and cardiovascular risk reduction. Eur Heart J. 2017;38:1823–1831.
   PubMed Web of Science ®Google Scholar
• Nordestgaard BG, Langsted A. How does elevated lipoprotein(a) cause aortic valve stenosis?. J Am Coll Cardiol. 2015;66:1247–1249.
   PubMed Web of Science ®Google Scholar
• Bergmark C, Dewan A, Orsoni A, et al. A novel function of lipoprotein [a] as a preferential carrier of oxidized phospholipids in human plasma. J Lipid Res. 2008;49:2230–2239.
   PubMed Web of Science ®Google Scholar
• Capoulade R, Chan KL, Yeang C, et al. Oxidized phospholipids, lipoprotein(a), and progression of calcific aortic valve stenosis. J Am Coll Cardiol. 2015;66:1236–1246.
   PubMed Web of Science ®Google Scholar
• Calabresi L, Gomaraschi M, Franceschini G. Endothelial protection by high-density lipoproteins: from bench to bedside. Arterioscler Thromb Vasc Biol. 2003;23:1724–1731.
   PubMed Web of Science ®Google Scholar
• Gomaraschi M, Basilico N, Sisto F, et al. High-density lipoproteins attenuate interleukin-6 production in endothelial cells exposed to pro-inflammatory stimuli. Biochim Biophys Acta. 2005;1736:136–143.
   PubMed Web of Science ®Google Scholar
• Theilmeier G, De Geest B, Van Veldhoven PP, et al. HDL-associated PAF-AH reduces endothelial adhesiveness in apoE-/- mice. Faseb J. 2000;14:2032–2039.
   PubMed Web of Science ®Google Scholar
• Favari E, Calabresi L, Adorni MP, et al. Small discoidal pre-beta1 HDL particles are efficient acceptors of cell cholesterol via ABCA1 and ABCG1. Biochemistry. 2009;48:11067–11074.
   PubMed Web of Science ®Google Scholar
• Honda S, Sidharta SL, Shishikura D, et al. High-density lipoprotein cholesterol associated with change in coronary plaque lipid burden assessed by near infrared spectroscopy. Atherosclerosis. 2017;265:110–116.
   PubMed Web of Science ®Google Scholar
• Zewinger S, Kleber ME, Rohrer L, et al. Symmetric dimethylarginine, high-density lipoproteins and cardiovascular disease. Eur Heart J. 2017;38:1597–1607.
   PubMed Web of Science ®Google Scholar
• Elliott P, Chambers JC, Zhang W, et al. Genetic Loci associated with C-reactive protein levels and risk of coronary heart disease. JAMA. 2009;302:37–48.
   PubMed Web of Science ®Google Scholar
• Collaboration CRPCHDG, Wensley F, Gao P, Burgess S, et al. Association between C reactive protein and coronary heart disease: mendelian randomisation analysis based on individual participant data. BMJ. 2011;342:d548.
   PubMedGoogle Scholar
• Lachmann HJ, Kone-Paut I, Kuemmerle-Deschner JB, et al. Use of canakinumab in the cryopyrin-associated periodic syndrome. N Engl J Med. 2009;360:2416–2425.
   PubMed Web of Science ®Google Scholar
• Capodanno D, Angiolillo DJ. Canakinumab for secondary prevention of atherosclerotic disease. Expert Opin Biol Ther. 2018;18:215–220.
   PubMed Web of Science ®Google Scholar
• Chakraborty A, Tannenbaum S, Rordorf C, et al. Pharmacokinetic and pharmacodynamic properties of canakinumab, a human anti-interleukin-1β monoclonal antibody . Clin Pharmacokinet. 2012;51:e1–18.
   PubMedGoogle Scholar
• Dhimolea E. Canakinumab. Mabs. 2010;2:3–13.
   PubMed Web of Science ®Google Scholar
• Wang W, Wang EQ, Balthasar JP. Monoclonal antibody pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther. 2008;84:548–558.
   PubMed Web of Science ®Google Scholar
• Sun H, Van LM, Floch D, et al. Pharmacokinetics and pharmacodynamics of canakinumab in patients with systemic juvenile idiopathic arthritis. J Clin Pharmacol. 2016;56:1516–1527.
   PubMed Web of Science ®Google Scholar
• Libby P. Interleukin-1 beta as a target for atherosclerosis therapy: biological basis of CANTOS and beyond. J Am Coll Cardiol. 2017;70:2278–2289.
   PubMed Web of Science ®Google Scholar
• Ridker PM, Everett BM, Thuren T, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med. 2017;377:1119–1131.
   PubMed Web of Science ®Google Scholar
• Ibanez B, Fuster V. CANTOS: A gigantic proof-of-concept trial. Circ Res. 2017;121:1320–1322.
   PubMed Web of Science ®Google Scholar
• Baylis RA, Gomez D, Mallat Z, et al. The CANTOS Trial: one important step for clinical cardiology but a giant leap for vascular biology. Arterioscler Thromb Vasc Biol. 2017;37:e174–e1e7.
   PubMed Web of Science ®Google Scholar
• Harrington RA. Targeting inflammation in coronary artery disease. N Engl J Med. 2017;377:1197–1198.
   PubMed Web of Science ®Google Scholar
• Ridker PM. Canakinumab for residual inflammatory risk. Eur Heart J. 2017;38:3545–3548.
   PubMed Web of Science ®Google Scholar
• Everett BM, Donath MY, Pradhan AD, et al. Anti-inflammatory therapy with canakinumab for the prevention and management of diabetes. J Am College Cardiol. 2018;71:2392–2401..
   PubMed Web of Science ®Google Scholar
• Lim GB. Diabetes: No benefit of canakinumab in diabetes prevention. Nat Rev Cardiol. 2018;15:256.
   Web of Science ®Google Scholar
• Ridker PM, MacFadyen JG, Everett BM, et al. Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial. Lancet. 2018;391:319–328.
   PubMed Web of Science ®Google Scholar
• Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005;366:1267–1278.
   PubMed Web of Science ®Google Scholar
• Bellosta S, Paoletti R, Corsini A. Safety of statins: focus on clinical pharmacokinetics and drug interactions. Circulation. 2004;109:III50–III57.
   PubMed Web of Science ®Google Scholar
• Bellosta S, Ferri N, Bernini F, et al. Non-lipid-related effects of statins. Ann Med. 2000;32:164–176.
   PubMed Web of Science ®Google Scholar
• Ferri N, Paoletti R, Corsini A. Lipid-modified proteins as biomarkers for cardiovascular disease: a review. Biomarkers: biochemical Indicators of Exposure, Response, and Susceptibility to Chemicals. 2005;10:219–237.
   PubMed Web of Science ®Google Scholar
• Diamantis E, Kyriakos G, Quiles-Sanchez LV, et al. The anti-inflammatory effects of statins on coronary artery disease: an updated review of the literature. Curr Cardiol Rev. 2017;13:209–216.
   PubMed Web of Science ®Google Scholar
• Corsini A, Ferri N, Cortellaro M. Are pleiotropic effects of statins real?. Vasc Health Risk Manag. 2007;3:611–613.
   PubMedGoogle Scholar
• Ferri N, Colombo G, Ferrandi C, et al. Simvastatin reduces MMP1 expression in human smooth muscle cells cultured on polymerized collagen by inhibiting Rac1 activation. Arterioscler Thromb Vasc Biol. 2007;27:1043–1049.
   PubMed Web of Science ®Google Scholar
• Khovidhunkit W, Kim MS, Memon RA, et al. Effects of infection and inflammation on lipid and lipoprotein metabolism: mechanisms and consequences to the host. J Lipid Res. 2004;45:1169–1196.
   PubMed Web of Science ®Google Scholar
• Ruscica M, Baragetti A, Catapano AL, et al. Translating the biology of adipokines in atherosclerosis and cardiovascular diseases: Gaps and open questions. Nutrition, Metabolism, and Cardiovascular Diseases: NMCD. 2017;27:379–395.
   PubMed Web of Science ®Google Scholar
• Ridker PM, Rifai N, Pfeffer MA, et al. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators. Circulation. 1998;98:839–844.
   PubMed Web of Science ®Google Scholar
• Nissen SE, Tuzcu EM, Schoenhagen P, et al. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N Engl J Med. 2005;352:29–38.
   PubMed Web of Science ®Google Scholar
• Ridker PM, Morrow DA, Rose LM, et al. Relative efficacy of atorvastatin 80 mg and pravastatin 40 mg in achieving the dual goals of low-density lipoprotein cholesterol <70 mg/dl and C-reactive protein <2 mg/l: an analysis of the PROVE-IT TIMI-22 trial. J Am Coll Cardiol. 2005;45:1644–1648.
   PubMed Web of Science ®Google Scholar
• Morrow DA, de Lemos JA, Sabatine MS, et al. Clinical relevance of C-reactive protein during follow-up of patients with acute coronary syndromes in the Aggrastat-to-Zocor Trial. Circulation. 2006;114:281–288.
   PubMed Web of Science ®Google Scholar
• Ridker PM, Cannon CP, Morrow D, et al. C-reactive protein levels and outcomes after statin therapy. N Engl J Med. 2005;352:20–28.
   PubMed Web of Science ®Google Scholar
• Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195–2207.
   PubMed Web of Science ®Google Scholar
• Ridker PM, Danielson E, Fonseca FA, et al. Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet. 2009;373:1175–1182.
   PubMed Web of Science ®Google Scholar
• Nissen SE, Tuzcu EM, Schoenhagen P, et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA. 2004;291:1071–1080.
   PubMed Web of Science ®Google Scholar
• Fichtlscherer S, Schmidt-Lucke C, Bojunga S, et al. Differential effects of short-term lipid lowering with ezetimibe and statins on endothelial function in patients with CAD: clinical evidence for 'pleiotropic' functions of statin therapy. Eur Heart J. 2006;27:1182–1190.
   PubMed Web of Science ®Google Scholar
• Reriani MK, Dunlay SM, Gupta B, et al. Effects of statins on coronary and peripheral endothelial function in humans: a systematic review and meta-analysis of randomized controlled trials. European Journal of Cardiovascular Prevention and Rehabilitation: official Journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology. 2011;18:704–716.
   PubMedGoogle Scholar
• Sposito AC, Santos SN, de Faria EC, et al. Timing and dose of statin therapy define its impact on inflammatory and endothelial responses during myocardial infarction. Arterioscler Thromb Vasc Biol. 2011;31:1240–1246.
   PubMed Web of Science ®Google Scholar
• Zacho J, Tybjaerg-Hansen A, Jensen JS, et al. Genetically elevated C-reactive protein and ischemic vascular disease. N Engl J Med. 2008;359:1897–1908.
   PubMed Web of Science ®Google Scholar
• Subramanian S, Emami H, Vucic E, et al. High-dose atorvastatin reduces periodontal inflammation: a novel pleiotropic effect of statins. J Am College Cardiol. 2013;62:2382–2391.
   PubMed Web of Science ®Google Scholar
• Altmann SW, Davis HR, Jr., Zhu LJ, et al. Niemann-Pick C1 Like 1 protein is critical for intestinal cholesterol absorption. Science. 2004;303:1201–1204.
   PubMed Web of Science ®Google Scholar
• Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. N Engl J Med. 2015;372:2387–2397.
   PubMed Web of Science ®Google Scholar
• Davidson MH. Ezetimibe: a novel option for lowering cholesterol. Expert Rev Cardiovascular Ther. 2003;1:11–21.
   PubMedGoogle Scholar
• Gomez-Garre D, Munoz-Pacheco P, Gonzalez-Rubio ML, et al. Ezetimibe reduces plaque inflammation in a rabbit model of atherosclerosis and inhibits monocyte migration in addition to its lipid-lowering effect. Br J Pharmacol. 2009;156:1218–1227.
   PubMed Web of Science ®Google Scholar
• Pearson TA, Ballantyne CM, Veltri E, et al. Pooled analyses of effects on C-reactive protein and low density lipoprotein cholesterol in placebo-controlled trials of ezetimibe monotherapy or ezetimibe added to baseline statin therapy. Am J Cardiol. 2009;103:369–374.
   PubMed Web of Science ®Google Scholar
• Bohula EA, Giugliano RP, Cannon CP, et al. Achievement of dual low-density lipoprotein cholesterol and high-sensitivity C-reactive protein targets more frequent with the addition of ezetimibe to simvastatin and associated with better outcomes in IMPROVE-IT. Circulation. 2015;132:1224–1233.
   PubMed Web of Science ®Google Scholar
• Storey BC, Staplin N, Haynes R, et al. Lowering LDL cholesterol reduces cardiovascular risk independently of presence of inflammation. Kidney Int. 2018;93:1000–1007.
   PubMed Web of Science ®Google Scholar
• Araujo DB, Bertolami MC, Ferreira WP, et al. Pleiotropic effects with equivalent low-density lipoprotein cholesterol reduction: comparative study between simvastatin and simvastatin/ezetimibe coadministration. J Cardiovasc Pharmacol. 2010;55:1–5.
   PubMed Web of Science ®Google Scholar
• Bulut D, Hanefeld C, Bulut-Streich N, et al. Endothelial function in the forearm circulation of patients with the metabolic syndrome-effect of different lipid-lowering regimens. Cardiology. 2005;104:176–180.
   PubMed Web of Science ®Google Scholar
• Kawagoe Y, Hattori Y, Nakano A, et al. Comparative study between high-dose fluvastatin and low-dose fluvastatin and ezetimibe with regard to the effect on endothelial function in diabetic patients. Endocr J. 2011;58:171–175.
   PubMed Web of Science ®Google Scholar
• Landmesser U, Bahlmann F, Mueller M, et al. Simvastatin versus ezetimibe: pleiotropic and lipid-lowering effects on endothelial function in humans. Circulation. 2005;111:2356–2363.
   PubMed Web of Science ®Google Scholar
• Liu PY, Liu YW, Lin LJ, et al. Evidence for statin pleiotropy in humans: differential effects of statins and ezetimibe on rho-associated coiled-coil containing protein kinase activity, endothelial function, and inflammation. Circulation. 2009;119:131–138.
   PubMed Web of Science ®Google Scholar
• Olijhoek JK, Hajer GR, van der Graaf Y, et al. The effects of low-dose simvastatin and ezetimibe compared to high-dose simvastatin alone on post-fat load endothelial function in patients with metabolic syndrome: a randomized double-blind crossover trial. J Cardiovasc Pharmacol. 2008;52:145–150.
   PubMed Web of Science ®Google Scholar
• Ostad MA, Eggeling S, Tschentscher P, et al. Flow-mediated dilation in patients with coronary artery disease is enhanced by high dose atorvastatin compared to combined low dose atorvastatin and ezetimibe: results of the CEZAR study. Atherosclerosis. 2009;205:227–232.
   PubMed Web of Science ®Google Scholar
• Settergren M, Bohm F, Ryden L, et al. Cholesterol lowering is more important than pleiotropic effects of statins for endothelial function in patients with dysglycaemia and coronary artery disease. Eur Heart J. 2008;29:1753–1760.
   PubMed Web of Science ®Google Scholar
• Westerink J, Deanfield JE, Imholz BP, et al. High-dose statin monotherapy versus low-dose statin/ezetimibe combination on fasting and postprandial lipids and endothelial function in obese patients with the metabolic syndrome: The PANACEA study. Atherosclerosis. 2013;227:118–124.
   PubMed Web of Science ®Google Scholar
• Grigore L, Raselli S, Garlaschelli K, et al. Effect of treatment with pravastatin or ezetimibe on endothelial function in patients with moderate hypercholesterolemia. Eur J Clin Pharmacol. 2013;69:341–346.
   PubMed Web of Science ®Google Scholar
• Ferri N, Corsini A, Sirtori C, et al. PPAR-α agonists are still on the rise: an update on clinical and experimental findings . Expert Opin Investig Drugs. 2017;26:593–602.
   PubMed Web of Science ®Google Scholar
• Botta M, Audano M, Sahebkar A, et al. PPAR agonists and metabolic syndrome: an established role? IJMS. 2018;19:1197.
   Google Scholar
• Elam MB, Ginsberg HN, Lovato LC, et al. Association of fenofibrate therapy with long-term cardiovascular risk in statin-treated patients with type 2 diabetes. JAMA Cardiol. 2017;2:370–380.
   PubMed Web of Science ®Google Scholar
• Telford M, Elisaf M. Clinical pharmacokinetics of fenofibrate. Curr Med Res Opin. 2003;19:139. author reply-40.
   PubMed Web of Science ®Google Scholar
• Hao Y, Zhang H, Yang X, et al. Effects of fibrates on C-reactive protein concentrations: a meta-analysis of randomized controlled trials. Clin Chem Lab Med. 2011;50:391–397.
   PubMed Web of Science ®Google Scholar
• Keech A, Simes RJ, Barter P, et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet. 2005;366:1849–1861.
   PubMed Web of Science ®Google Scholar
• Hiukka A, Westerbacka J, Leinonen ES, et al. Long-term effects of fenofibrate on carotid intima-media thickness and augmentation index in subjects with type 2 diabetes mellitus. J Am Coll Cardiol. 2008;52:2190–2197.
   PubMed Web of Science ®Google Scholar
• Fievet C, Staels B. Combination therapy of statins and fibrates in the management of cardiovascular risk. Curr Opin Lipidol. 2009;20:505–511.
   PubMed Web of Science ®Google Scholar
• Corsini A, Bellosta S, Davidson MH. Pharmacokinetic interactions between statins and fibrates. Am J Cardiol. 2005;96:44K–49K. discussion 34K-5K.
   PubMed Web of Science ®Google Scholar
• Muhlestein JB, May HT, Jensen JR, et al. The reduction of inflammatory biomarkers by statin, fibrate, and combination therapy among diabetic patients with mixed dyslipidemia: the DIACOR (Diabetes and Combined Lipid Therapy Regimen) study. J Am Coll Cardiol. 2006;48:396–401.
   PubMed Web of Science ®Google Scholar
• Kei A, Liberopoulos E, Tellis K, et al. Effect of hypolipidemic treatment on emerging risk factors in mixed dyslipidemia: a randomized pilot trial. Eur J Clin Invest. 2013;43:698–707.
   PubMed Web of Science ®Google Scholar
• Agouridis AP, Tsimihodimos V, Filippatos TD, et al. The effects of rosuvastatin alone or in combination with fenofibrate or omega 3 fatty acids on inflammation and oxidative stress in patients with mixed dyslipidemia. Expert Opin Pharmacother. 2011;12:2605–2611.
   PubMed Web of Science ®Google Scholar
• McKenney JM, Farnier M, Lo KW, et al. Safety and efficacy of long-term co-administration of fenofibrate and ezetimibe in patients with mixed hyperlipidemia. J Am College Cardiol. 2006;47:1584–1587.
   PubMed Web of Science ®Google Scholar
• Ferri N, Corsini A, Macchi C, et al. Proprotein convertase subtilisin kexin type 9 and high-density lipoprotein metabolism: experimental animal models and clinical evidence. Transl Res. 2016;173:19–29.
   PubMed Web of Science ®Google Scholar
• Norata GD, Tavori H, Pirillo A, et al. Biology of proprotein convertase subtilisin kexin 9: beyond low-density lipoprotein cholesterol lowering. Cardiovasc Res. 2016;112:429–442.
   PubMed Web of Science ®Google Scholar
• Ferri N, Ruscica M. Proprotein convertase subtilisin/kexin type 9 (PCSK9) and metabolic syndrome: insights on insulin resistance, inflammation, and atherogenic dyslipidemia. Endocrine 2016;54:588–601.
   PubMed Web of Science ®Google Scholar
• Ferri N, Corsini A, Sirtori CR, et al. Bococizumab for the treatment of hypercholesterolemia. Expert Opin Biol Ther. 2017;17:237–243.
   PubMed Web of Science ®Google Scholar
• Ferri N, Corsini A, Sirtori CR, et al. Bococizumab for the treatment of hypercholesterolemia. Expert Opin Biol Ther. 2017;17:909–910.
   PubMed Web of Science ®Google Scholar
• Nordestgaard BG, Nicholls SJ, Langsted A, et al. Advances in lipid-lowering therapy through gene-silencing technologies. Nat Rev Cardiol. 2018;15:261–272.
   PubMed Web of Science ®Google Scholar
• Landlinger C, Pouwer MG, Juno C, et al. The AT04A vaccine against proprotein convertase subtilisin/kexin type 9 reduces total cholesterol, vascular inflammation, and atherosclerosis in APOE*3Leiden.CETP mice. Eur Heart J. 2017;38:2499–2507.
   PubMed Web of Science ®Google Scholar
• Kasichayanula S, Grover A, Emery MG, et al. Clinical Pharmacokinetics and Pharmacodynamics of Evolocumab, a PCSK9 Inhibitor. ClinPharmacokinet 2018;57:769–779.
   PubMed Web of Science ®Google Scholar
• U.S. S-A. Praluent (alirocumab injection) prescribing information. 2015.
   Google Scholar
• Ferri N, Bellosta S, Baldessin L, et al. Pharmacokinetics interactions of monoclonal antibodies. Pharmacol Res. 2016;111:592–599.
   PubMed Web of Science ®Google Scholar
• Evolocumab. REPATHA (evolocumab). 2017.
   Google Scholar
• Qian LJ, Gao Y, Zhang YM, et al. Therapeutic efficacy and safety of PCSK9-monoclonal antibodies on familial hypercholesterolemia and statin-intolerant patients: A meta-analysis of 15 randomized controlled trials. Sci Rep. 2017;7:238.
   PubMed Web of Science ®Google Scholar
• Masana L, Girona J, Ibarretxe D, et al. Clinical and pathophysiological evidence supporting the safety of extremely low LDL levels-The zero-LDL hypothesis. J Clin Lipidol. 2018;12:292–299.e3.
   PubMed Web of Science ®Google Scholar
• Reiner Z. PCSK9 inhibitors in clinical practice: Expectations and reality. Atherosclerosis 2018;270:187–188.
   PubMed Web of Science ®Google Scholar
• Karatasakis A, Danek BA, Karacsonyi J, et al. Effect of PCSK9 Inhibitors on clinical outcomes in patients with hypercholesterolemia: a meta-analysis of 35 randomized controlled trials. J Am Heart Assoc. 2017;6:e006910.
   PubMed Web of Science ®Google Scholar
• Bai J, Gong LL, Li QF, et al. Long-term efficacy and safety of proprotein convertase subtilisin/kexin 9 monoclonal antibodies: A meta-analysis of 11 randomized controlled trials. J Clin Lipidol. 2018;12:277–291.e3.
   PubMed Web of Science ®Google Scholar
• Welder G, Zineh I, Pacanowski MA, et al. High-dose atorvastatin causes a rapid sustained increase in human serum PCSK9 and disrupts its correlation with LDL cholesterol. J Lipid Res. 2010;51:2714–2721.
   PubMed Web of Science ®Google Scholar
• Baragetti A, Grejtakova D, Casula M, et al. Proprotein Convertase Subtilisin-Kexin type-9 (PCSK9) and triglyceride-rich lipoprotein metabolism: Facts and gaps. Pharmacol Res. 2018;130:1–11.
   PubMed Web of Science ®Google Scholar
• Tavori H, Christian D, Minnier J, et al. PCSK9 association with lipoprotein(a). Circ Res. 2016;119:29–35.
   PubMed Web of Science ®Google Scholar
• Guardiola M, Plana N, Ibarretxe D, et al. Circulating PCSK9 levels are positively correlated with NMR-assessed atherogenic dyslipidaemia in patients with high cardiovascular risk. Clin Sci. 2015;128:877–882.
   PubMed Web of Science ®Google Scholar
• Ruscica M, Ferri N, Fogacci F, et al. Circulating levels of proprotein convertase subtilisin/kexin type 9 and arterial stiffness in a large population sample: data from the Brisighella Heart Study. J Am Heart Assoc. 2017;6:e005764.
   PubMed Web of Science ®Google Scholar
• Camera M, Rossetti L, Barbieri SS, et al. PCSK9 as a Positive Modulator of Platelet Activation. J Am Coll Cardiol. 2018;71:952–954.
   PubMed Web of Science ®Google Scholar
• Ruscica M, Simonelli S, Botta M, et al. Plasma PCSK9 levels and lipoprotein distribution are preserved in carriers of genetic HDL disorders. Biochim Biophys Acta. 2018;1863:991–997.
   Web of Science ®Google Scholar
• Ruscica M, Ferri N, Macchi C, et al. Liver fat accumulation is associated with circulating PCSK9. Ann Med. 2016;48:384–391.
   PubMed Web of Science ®Google Scholar
• Ricci C, Ruscica M, Camera M, et al. PCSK9 induces a pro-inflammatory response in macrophages. Sci Rep. 2018;8:2267.
   PubMedGoogle Scholar
• Ridker PM, Rifai N, Bradwin G, et al. Plasma proprotein convertase subtilisin/kexin type 9 levels and the risk of first cardiovascular events. Eur Heart J. 2016;37:554–560.
   PubMed Web of Science ®Google Scholar
• Sahebkar A, Di Giosia P, Stamerra CA, et al. Effect of monoclonal antibodies to PCSK9 on high-sensitivity C-reactive protein levels: a meta-analysis of 16 randomized controlled treatment arms. Br J Clin Pharmacol. 2016;81:1175–1190.
   PubMed Web of Science ®Google Scholar
• Ruscica M, Ferri N, Corsini A, et al. PCSK9 antagonists and inflammation. Atherosclerosis. 2018;268:235–236.
   PubMed Web of Science ®Google Scholar
• Cannon CP, Cariou B, Blom D, et al. Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial. Eur Heart J. 2015;36:1186–1194.
   PubMed Web of Science ®Google Scholar
• Ray KK, Landmesser U, Leiter LA, et al. Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol. N Engl J Med. 2017;376:1430–1440.
   PubMed Web of Science ®Google Scholar
• Ridker PM. Mortality differences associated with treatment responses in CANTOS and FOURIER: insights and implications. Circulation. 2018;137:1763–1766.
   PubMed Web of Science ®Google Scholar
• Bohula EA, Giugliano RP, Leiter LA, et al. Inflammatory and Cholesterol Risk in the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Patients With Elevated Risk). Circulation 2018;138:131–140.
   PubMed Web of Science ®Google Scholar
• Catapano AL, Pirillo A, Norata GD. Vascular inflammation and low-density lipoproteins: is cholesterol the link? A lesson from the clinical trials. Br J Pharmacol. 2017;174:3973–3985.
   PubMed Web of Science ®Google Scholar
• Sabatine MS, De Ferrari GM, Giugliano RP, et al. Clinical Benefit of Evolocumab by Severity and Extent of Coronary Artery Disease: An Analysis from FOURIER. Circulation. 2018. DOI: 10.1161/CIRCULATIONAHA.118.034309.
   Web of Science ®Google Scholar
• Pocock SJ, Collier TJ. Critical Appraisal of the 2018 ACC Scientific Sessions Late-Breaking Trials From a Statistician's Perspective. J Am Coll Cardiol 2018;71:2957–2969.
   PubMed Web of Science ®Google Scholar
• Steg P. The ODYSSEY Outcomes Trial: Topline Results. Paper presented at: American College of Cardiology Annual Scientific Session. 2018.
   Google Scholar
• Schwartz GG, Bessac L, Berdan LG, et al. Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trial. Am Heart J. 2014;168:682–689.
   PubMed Web of Science ®Google Scholar
• Pradhan AD, Aday AW, Rose LM, et al. Residual Inflammatory Risk On Treatment with PCSK9 Inhibition and Statin Therapy. Circulation. 2018;138:141–149.
   PubMed Web of Science ®Google Scholar
• Yin RX, Wu JZ, Liu WY, et al. Association of several lipid-related gene polymorphisms and blood pressure variation in the Bai Ku Yao population. Am J Hypertens. 2012;25:927–936.
   PubMed Web of Science ®Google Scholar
• Tran NT, Aslibekyan S, Tiwari HK, et al. PCSK9 variation and association with blood pressure in African Americans: preliminary findings from the HyperGEN and REGARDS studies. Front Genet. 2015;6:136.
   PubMed Web of Science ®Google Scholar
• Hachem A, Hariri E, Saoud P, et al. The role of proprotein convertase subtilisin/kexin type 9 (PCSK9) in cardiovascular homeostasis: a non-systematic literature review. Curr Cardiol Rev 2017;13:274–282.
   PubMed Web of Science ®Google Scholar
• Ray KK, Stoekenbroek RM, Kallend D, et al. Effect of an siRNA therapeutic targeting PCSK9 on atherogenic lipoproteins: pre-specified secondary end points in ORION 1. Circulation. 2018. DOI: 10.1161/CIRCULATIONAHA.118.034710
   Web of Science ®Google Scholar
• Raal FJ, Giugliano RP, Sabatine MS, et al. PCSK9 inhibition-mediated reduction in Lp(a) with evolocumab: an analysis of 10 clinical trials and the LDL receptor's role. J Lipid Res. 2016;57:1086–1096.
   PubMed Web of Science ®Google Scholar
• Watts GF, Chan DC, Somaratne R, et al. Controlled study of the effect of proprotein convertase subtilisin-kexin type 9 inhibition with evolocumab on lipoprotein(a) particle kinetics. Eur Heart J. 2018;39:2577–2585.
   PubMed Web of Science ®Google Scholar
• Reyes-Soffer G, Pavlyha M, Ngai C, et al. Effects of PCSK9 inhibition with alirocumab on lipoprotein metabolism in healthy humans. Circulation. 2017;135:352–362.
   PubMed Web of Science ®Google Scholar
• Saleheen D, Haycock PC, Zhao W, et al. Apolipoprotein(a) isoform size, lipoprotein(a) concentration, and coronary artery disease: a mendelian randomisation analysis. Lancet Diab Endocrinol. 2017;5:524–533.
   PubMed Web of Science ®Google Scholar
• Villard EF, Thedrez A, Blankenstein J, et al. PCSK9 modulates the secretion but not the cellular uptake of lipoprotein(a) ex vivo: an effect blunted by alirocumab. JACC Basic Transl Sci. 2016;1:419–427.
   PubMedGoogle Scholar
• Pirillo A, Catapano AL. PCSK9 inhibition and Lp(a) reduction: another piece of the puzzle? Eur Heart J. 2018;39:2586–2588.
   PubMed Web of Science ®Google Scholar
• The Lipid Research Clinics Coronary Primary Prevention Trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA. 1984;251:365–374.
   PubMed Web of Science ®Google Scholar
• Dorr AE, Gundersen K, Schneider JC, Jr, et al. Colestipol hydrochloride in hypercholesterolemic patients–effect on serum cholesterol and mortality. J Chro Dis. 1978;31:5–14.
   PubMedGoogle Scholar
• Bays H, Dujovne C. Colesevelam HCl: a non-systemic lipid-altering drug. Expert Opin Pharmacother. 2003;4:779–790.
   PubMed Web of Science ®Google Scholar
• Bays HE, Davidson M, Jones MR, et al. Effects of colesevelam hydrochloride on low-density lipoprotein cholesterol and high-sensitivity C-reactive protein when added to statins in patients with hypercholesterolemia. Am J Cardiol. 2006;97:1198–1205.
   PubMed Web of Science ®Google Scholar
• Kato T, Inagaki K, Sawai Y, et al. Comparison of efficacy of pitavastatin and colestimide in Japanese patients with diabetes mellitus complicated by hyperlipidemia and metabolic syndrome. Exp Clin Endocrinol Diabetes. 2011;119:554–558.
   PubMed Web of Science ®Google Scholar
• Sirtori CR, Pavanello C, Bertolini S. Microsomal transfer protein (MTP) inhibition-a novel approach to the treatment of homozygous hypercholesterolemia. Ann Med. 2014;46:464–474.
   PubMed Web of Science ®Google Scholar
• information LD. JUXTAPID® (lomitapide) capsules, for oral use. 2016.
   Google Scholar
• Berberich AJ, Hegele RA. Lomitapide for the treatment of hypercholesterolemia. Expert Opin Pharmacother. 2017;18:1261–1268.
   PubMed Web of Science ®Google Scholar
• Blom DJ, Averna MR, Meagher EA, et al. Long-term efficacy and safety of the microsomal triglyceride transfer protein inhibitor lomitapide in patients with homozygous familial hypercholesterolemia. Circulation. 2017;136:332–335.
   PubMed Web of Science ®Google Scholar
• Frolov RV, Ignatova II, Singh S. Inhibition of HERG potassium channels by celecoxib and its mechanism. PLoS One. 2011;6:e26344
   PubMed Web of Science ®Google Scholar
• Geary RS, Baker BF, Crooke ST. Clinical and preclinical pharmacokinetics and pharmacodynamics of mipomersen (kynamro(®)): a second-generation antisense oligonucleotide inhibitor of apolipoprotein B . Clin Pharmacokinet. 2015;54:133–146.
   PubMed Web of Science ®Google Scholar
• Injection KmsISfS. HIGHLIGHTS OF PRESCRIBING INFORMATION. 2016.
   Google Scholar
• Flaim JD, Grundy JS, Baker BF, et al. Changes in mipomersen dosing regimen provide similar exposure with improved tolerability in randomized placebo-controlled study of healthy volunteers. J Am Heart Assoc. 2014;3:e000560.
   PubMed Web of Science ®Google Scholar
• Duell PB, Santos RD, Kirwan BA, et al. Long-term mipomersen treatment is associated with a reduction in cardiovascular events in patients with familial hypercholesterolemia. Journal of Clinical Lipidology. 2016;10:1011–1021.
   PubMed Web of Science ®Google Scholar
• Pinkosky SL, Groot PHE, Lalwani ND, et al. Targeting ATP-Citrate Lyase in Hyperlipidemia and Metabolic Disorders. Trends Mol Med. 2017;23:1047–1063.
   PubMed Web of Science ®Google Scholar
• Ference B, Neff D, Cabot M, et al. GENETIC TARGET VALIDATION FOR ATP-CITRATE LYASE INHIBITION. J Am Coll Cardiol. 2017;69:1655.
   Web of Science ®Google Scholar
• Burke AC, Huff MW. ATP-citrate lyase: genetics, molecular biology and therapeutic target for dyslipidemia. Curr Opin Lipidol. 2017;28:193–200.
   PubMed Web of Science ®Google Scholar
• Pinkosky SL, Newton RS, Day EA, et al. Liver-specific ATP-citrate lyase inhibition by bempedoic acid decreases LDL-C and attenuates atherosclerosis. Nat Comms. 2016;7:13457.
   PubMed Web of Science ®Google Scholar
• Gutierrez MJ, Rosenberg NL, Macdougall DE, et al. Efficacy and safety of ETC-1002, a novel investigational low-density lipoprotein-cholesterol-lowering therapy for the treatment of patients with hypercholesterolemia and type 2 diabetes mellitus. Arteriosclerosis, Thrombosis, and Vascular Biology. 2014;34:676–683.
   PubMed Web of Science ®Google Scholar
• Ballantyne CM, Davidson MH, Macdougall DE, et al. Efficacy and safety of a novel dual modulator of adenosine triphosphate-citrate lyase and adenosine monophosphate-activated protein kinase in patients with hypercholesterolemia: results of a multicenter, randomized, double-blind, placebo-controlled, parallel-group trial. J Am Coll Cardiol. 2013;62:1154–1162.
   PubMed Web of Science ®Google Scholar
• Thompson PD, Rubino J, Janik MJ, et al. Use of ETC-1002 to treat hypercholesterolemia in patients with statin intolerance. J Clin Lipidol. 2015;9:295–304.
   PubMed Web of Science ®Google Scholar
• Ballantyne CM, Banach M, Mancini GBJ, et al. Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: A randomized, placebo-controlled study. Atherosclerosis. 2018; Available online 12 June 2018.
   Google Scholar
• Saeed A, Ballantyne CM. Bempedoic acid (ETC-1002): a current review. Cardiol Clin. 2018;36:257–264.
   PubMed Web of Science ®Google Scholar
• Thompson PD, MacDougall DE, Newton RS, et al. Treatment with ETC-1002 alone and in combination with ezetimibe lowers LDL cholesterol in hypercholesterolemic patients with or without statin intolerance. J Clin Lipidol. 2016;10:556–567.
   PubMed Web of Science ®Google Scholar
• Barter PJ, Rye KA. Cholesteryl ester transfer protein inhibitors as agents to reduce coronary heart disease risk. Cardiol Clin. 2018;36:299–310.
   PubMed Web of Science ®Google Scholar
• Tall AR, Rader DJ. Trials and tribulations of CETP inhibitors. Circ Res. 2018;122:106–112.
   PubMed Web of Science ®Google Scholar
• Shrestha S, Wu BJ, Guiney L, et al. Cholesteryl ester transfer protein and its inhibitors. J Lipid Res. 2018;59:772–783.
   PubMed Web of Science ®Google Scholar
• Barter P, Gotto AM, LaRosa JC, et al. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med. 2007;357:1301–1310.
   PubMed Web of Science ®Google Scholar
• Lincoff AM, Nicholls SJ, Riesmeyer JS, et al. Evacetrapib and cardiovascular outcomes in high-risk vascular disease. N Engl J Med. 2017;376:1933–1942.
   PubMed Web of Science ®Google Scholar
• Group HTRC, Bowman L, Hopewell JC, Chen F, et al. Effects of anacetrapib in patients with atherosclerotic vascular disease. N Engl J Med. 2017;377:1217–1227.
   PubMed Web of Science ®Google Scholar
• Schwartz GG, Olsson AG, Abt M, et al. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med. 2012;367:2089–2099.
   PubMed Web of Science ®Google Scholar
• Tardif JC, Rhainds D, Brodeur M, et al. Genotype-dependent effects of dalcetrapib on cholesterol efflux and inflammation: concordance with clinical outcomes. Circulation Cardiovascular Genetics 2016;9:340–348.
   PubMed Web of Science ®Google Scholar
• Digby JE, Ruparelia N, Choudhury RP. Niacin in cardiovascular disease: recent preclinical and clinical developments. Arteriosclerosis, Thrombosis, and Vascular Biology. 2012;32:582–588.
   PubMed Web of Science ®Google Scholar
• Wang W, Basinger A, Neese RA, et al. Effect of nicotinic acid administration on hepatic very low density lipoprotein-triglyceride production. Am J Physiol Endocrinol Metab. 2001;280:E540–E547.
   PubMed Web of Science ®Google Scholar
• Watt MJ, Southgate RJ, Holmes AG, et al. Suppression of plasma free fatty acids upregulates peroxisome proliferator-activated receptor (PPAR) alpha and delta and PPAR coactivator 1alpha in human skeletal muscle, but not lipid regulatory genes. J Molecul Endocrinol. 2004;33:533–544.
   PubMed Web of Science ®Google Scholar
• Vega GL, Cater NB, Meguro S, et al. Influence of extended-release nicotinic acid on nonesterified fatty acid flux in the metabolic syndrome with atherogenic dyslipidemia. Am J Cardiol. 2005;95:1309–1313.
   PubMed Web of Science ®Google Scholar
• Fuccella LM, Goldaniga G, Lovisolo P, et al. Inhibition of lipolysis by nicotinic acid and by acipimox. Clin Pharmacol Ther. 1980;28:790–795.
   PubMed Web of Science ®Google Scholar
• Montecucco F, Bertolotto M, Vuilleumier N, et al. Acipimox reduces circulating levels of insulin and associated neutrophilic inflammation in metabolic syndrome. Am J Physiol Endocrinol Metab. 2011;300:E681–E690.
   PubMed Web of Science ®Google Scholar
• Investigators A-H, Boden WE, Probstfield JL, et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med. 2011;365:2255–2267.
   PubMed Web of Science ®Google Scholar
• Group HTC, Landray MJ, Haynes R, Hopewell JC, et al. Effects of extended-release niacin with laropiprant in high-risk patients. N Engl J Med. 2014;371:203–212.
   PubMed Web of Science ®Google Scholar
• Superko HR, Zhao XQ, Hodis HN, et al. Niacin and heart disease prevention: Engraving its tombstone is a mistake. J Clin Lipidol. 2017;11:1309–1317.
   PubMed Web of Science ®Google Scholar
• Rotter V, Nagaev I, Smith U. Interleukin-6 (IL-6) induces insulin resistance in 3T3-L1 adipocytes and is, like IL-8 and tumor necrosis factor-alpha, overexpressed in human fat cells from insulin-resistant subjects. J Biol Chem. 2003;278:45777–45784.
   PubMed Web of Science ®Google Scholar
• Franceschini G, Bernini F, Michelagnoli S, et al. Lipoprotein changes and increased affinity of LDL for their receptors after acipimox treatment in hypertriglyceridemia. Atherosclerosis. 1990;81:41–49.
   PubMed Web of Science ®Google Scholar
• Adiels M, Chapman MJ, Robillard P, et al. Niacin action in the atherogenic mixed dyslipidemia of metabolic syndrome: Insights from metabolic biomarker profiling and network analysis. J Clin Lipidol. 2018;12:810–821.e1.
   PubMed Web of Science ®Google Scholar
• Feingold KR, Moser A, Shigenaga JK, et al. Inflammation stimulates niacin receptor (GPR109A/HCA2) expression in adipose tissue and macrophages. J Lipid Res. 2014;55:2501–2508.
   PubMed Web of Science ®Google Scholar
• Singh N, Gurav A, Sivaprakasam S, et al. Activation of Gpr109a, receptor for niacin and the commensal metabolite butyrate, suppresses colonic inflammation and carcinogenesis. Immunity. 2014;40:128–139.
   PubMed Web of Science ®Google Scholar
• Wu BJ, Yan L, Charlton F, et al. Evidence that niacin inhibits acute vascular inflammation and improves endothelial dysfunction independent of changes in plasma lipids. Arteriosclerosis, Thrombosis, and Vascular Biology. 2010;30:968–975.
   PubMed Web of Science ®Google Scholar
• Wi J, Kim JY, Park S, et al. Optimal pharmacologic approach to patients with hypertriglyceridemia and low high-density lipoprotein-cholesterol: randomized comparison of fenofibrate 160 mg and niacin 1500 mg. Atherosclerosis. 2010;213:235–240.
   PubMed Web of Science ®Google Scholar
• Everett BM, Pradhan AD, Solomon DH, et al. Rationale and design of the Cardiovascular Inflammation Reduction Trial: a test of the inflammatory hypothesis of atherothrombosis. Am Heart J. 2013;166:199–207 e15.
   PubMed Web of Science ®Google Scholar
• (NCT02551094) CCOT.
   Google Scholar
• Martinez GJ, Celermajer DS, Patel S. The NLRP3 inflammasome and the emerging role of colchicine to inhibit atherosclerosis-associated inflammation. Atherosclerosis. 2018;269:262–271.
   PubMed Web of Science ®Google Scholar
• Reklou A, Doumas M, Imprialos K, et al. Reduction of Vascular Inflammation, LDL-C, or Both for the Protection from Cardiovascular Events? Open Cardiovasc Med J. 2018;12:29–40.
   PubMed Web of Science ®Google Scholar
• Maseri A. Inflammation, atherosclerosis, and ischemic events - exploring the hidden side of the moon. N Engl J Med. 1997;336:1014–1016.
   PubMed Web of Science ®Google Scholar
• Braunwald E. Creating controversy where none exists: the important role of C-reactive protein in the CARE, AFCAPS/TexCAPS, PROVE IT, REVERSAL, A to Z, JUPITER, HEART PROTECTION, and ASCOT trials. Eur Heart J. 2012;33:430–432.
   PubMed Web of Science ®Google Scholar
• Ruscica M, Macchi C, Pavanello C, et al. Appropriateness of statin prescription in the elderly. Eur J Intern Med 2018;50:33–40.
   PubMed Web of Science ®Google Scholar
• Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med. 1996;335:1001–1009.
   PubMed Web of Science ®Google Scholar
• Ridker PM, Rifai N, Pfeffer MA, et al. Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators. Circulation 1999;100:230–235.
   PubMed Web of Science ®Google Scholar
• Albert MA, Danielson E, Rifai N, et al. Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. JAMA. 2001;286:64–70.
   PubMed Web of Science ®Google Scholar
• Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA. 1998;279:1615–1622.
   PubMed Web of Science ®Google Scholar
• Kinlay S, Schwartz GG, Olsson AG, et al. High-dose atorvastatin enhances the decline in inflammatory markers in patients with acute coronary syndromes in the MIRACL study. Circulation. 2003;108:1560–1566.
   PubMed Web of Science ®Google Scholar
• Schwartz GG, Olsson AG, Ezekowitz MD, et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA. 2001;285:1711–1718.
   PubMed Web of Science ®Google Scholar
• Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004;350:1495–1504.
   PubMed Web of Science ®Google Scholar
• de Lemos JA, Blazing MA, Wiviott SD, et al. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA. 2004;292:1307–1316.
   PubMed Web of Science ®Google Scholar
• Heart Protection Study Collaborative G, Jonathan E, Derrick B, Emma L, et al. C-reactive protein concentration and the vascular benefits of statin therapy: an analysis of 20,536 patients in the Heart Protection Study. Lancet. 2011;377:9764469–9764476.
   Web of Science ®Google Scholar
• Sever PS, Poulter NR, Chang CL, et al. Evaluation of C-reactive protein before and on-treatment as a predictor of benefit of atorvastatin: a cohort analysis from the Anglo-Scandinavian Cardiac Outcomes Trial lipid-lowering arm. J Am Coll Cardiol. 2013;62:717–729.
   PubMed Web of Science ®Google Scholar
• Soedamah-Muthu SS, Livingstone SJ, Charlton-Menys V, et al. Effect of atorvastatin on C-reactive protein and benefits for cardiovascular disease in patients with type 2 diabetes: analyses from the Collaborative Atorvastatin Diabetes Trial. Diabetologia. 2015;58:1494–1502.
   PubMed Web of Science ®Google Scholar
• Ballantyne CM, Houri J, Notarbartolo A, et al. Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial. Circulation. 2003;107:2409–2415.
   PubMed Web of Science ®Google Scholar
• Ballantyne CM, Weiss R, Moccetti T, et al. Efficacy and safety of rosuvastatin 40 mg alone or in combination with ezetimibe in patients at high risk of cardiovascular disease (results from the EXPLORER study). Am J Cardiol. 2007;99:673–680.
   PubMed Web of Science ®Google Scholar
• Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. N Engl J Med. 2017;376:1713–1722.
   PubMed Web of Science ®Google Scholar